1-Year Outcomes of a Leadless Ventricular Pacemaker: The LEADLESS II (Phase 2) Trial

LEADLESS II Investigators

doi:10.1016/j.jacep.2023.01.031

1-Year Outcomes of a Leadless Ventricular Pacemaker: The LEADLESS II (Phase 2) Trial

LEADLESS II Investigators

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English
Pages (from-to)	1187-1189
Number of pages	3
Journal	JACC: Clinical Electrophysiology
Volume	9
Issue number	7
DOIs	https://doi.org/10.1016/j.jacep.2023.01.031
State	Published - Jul 2023

Access to Document

10.1016/j.jacep.2023.01.031

Cite this

@article{3ae54caf508144efafd90b2e1273d101,

title = "1-Year Outcomes of a Leadless Ventricular Pacemaker: The LEADLESS II (Phase 2) Trial",

author = "{LEADLESS II Investigators} and Reddy, {Vivek Y.} and Exner, {Derek V.} and Rahul Doshi and Gery Tomassoni and Bunch, {T. Jared} and Paul Friedman and Estes, {N. A.Mark} and Petr Neu{\v z}il and {de la Concha}, {Joaquin Fernandez} and Cantillon, {Daniel J.}",

note = "Funding Information: Abbott provided funding for the LEADLESS II (phase 2) trial. Dr Reddy is a consultant for Abbott; also, unrelated to this paper, he has served as a consultant for and has equity in Ablacon, Acutus Medical, Affera-Medtronic, Apama Medical-Boston Scientific, APN Health, Aquaheart, Atacor, Autonomix, Axon Therapies, Backbeat, BioSig, CardiaCare, CardioNXT / AFTx, Circa Scientific, CoRISMA, Corvia Medical, Dinova-Hangzhou DiNovA EP Technology, East End Medical, EPD-Philips, EP Frontiers, Epix Therapeutics-Medtronic, EpiEP, Eximo, Farapulse-Boston Scientific, Field Medical, Focused Therapeutics, HRT, Intershunt, Javelin, Kardium, Keystone Heart, LuxMed, Medlumics, Middlepeak, Neutrace, Nuvera-Biosense Webster, Oracle Health, Restore Medical, Sirona Medical, SoundCath, and Valcare; unrelated to this work, has served as a consultant for Abbott, AtriAN, Biosense Webster, BioTel Heart, Biotronik, Boston Scientific, Cairdac, Cardiofocus, Cardionomic, CoreMap, Fire1, Gore & Associates, Impulse Dynamics, Medtronic, Philips, and Pulse Biosciences; and has equity in Manual Surgical Sciences, Newpace, Nyra Medical, Surecor, and Vizaramed. Dr Exner is a consultant for and receives research support from Abbott. Dr Doshi is a consultant for Abbott. Dr Tomassoni is a consultant and speaker for Abbott and Boston Scientific. Dr Bunch is a consultant for Abbott; and has received research grants from Altathera and Boston Scientific. Dr Friedman serves as an advisory board member for Medtronic, Boston Scientific, and Abbott. Dr Estes is a consultant for Abbott, Medtronic, and Boston Scientific. Dr Fernandez de la Concha is a consultant for Abbott, Medtronic, and Biotronik. Dr Cantillon is a consultant for Abbott and Boston Scientific. Dr Neu{\v z}il has reported that he has no relationships relevant to the contents of this paper to disclose. ",

year = "2023",

month = jul,

doi = "10.1016/j.jacep.2023.01.031",

language = "English",

volume = "9",

pages = "1187--1189",

journal = "JACC: Clinical Electrophysiology",

issn = "2405-500X",

publisher = "Elsevier USA",

number = "7",

}

TY - JOUR

T1 - 1-Year Outcomes of a Leadless Ventricular Pacemaker

T2 - The LEADLESS II (Phase 2) Trial

AU - LEADLESS II Investigators

AU - Reddy, Vivek Y.

AU - Exner, Derek V.

AU - Doshi, Rahul

AU - Tomassoni, Gery

AU - Bunch, T. Jared

AU - Friedman, Paul

AU - Estes, N. A.Mark

AU - Neužil, Petr

AU - de la Concha, Joaquin Fernandez

AU - Cantillon, Daniel J.

N1 - Funding Information: Abbott provided funding for the LEADLESS II (phase 2) trial. Dr Reddy is a consultant for Abbott; also, unrelated to this paper, he has served as a consultant for and has equity in Ablacon, Acutus Medical, Affera-Medtronic, Apama Medical-Boston Scientific, APN Health, Aquaheart, Atacor, Autonomix, Axon Therapies, Backbeat, BioSig, CardiaCare, CardioNXT / AFTx, Circa Scientific, CoRISMA, Corvia Medical, Dinova-Hangzhou DiNovA EP Technology, East End Medical, EPD-Philips, EP Frontiers, Epix Therapeutics-Medtronic, EpiEP, Eximo, Farapulse-Boston Scientific, Field Medical, Focused Therapeutics, HRT, Intershunt, Javelin, Kardium, Keystone Heart, LuxMed, Medlumics, Middlepeak, Neutrace, Nuvera-Biosense Webster, Oracle Health, Restore Medical, Sirona Medical, SoundCath, and Valcare; unrelated to this work, has served as a consultant for Abbott, AtriAN, Biosense Webster, BioTel Heart, Biotronik, Boston Scientific, Cairdac, Cardiofocus, Cardionomic, CoreMap, Fire1, Gore & Associates, Impulse Dynamics, Medtronic, Philips, and Pulse Biosciences; and has equity in Manual Surgical Sciences, Newpace, Nyra Medical, Surecor, and Vizaramed. Dr Exner is a consultant for and receives research support from Abbott. Dr Doshi is a consultant for Abbott. Dr Tomassoni is a consultant and speaker for Abbott and Boston Scientific. Dr Bunch is a consultant for Abbott; and has received research grants from Altathera and Boston Scientific. Dr Friedman serves as an advisory board member for Medtronic, Boston Scientific, and Abbott. Dr Estes is a consultant for Abbott, Medtronic, and Boston Scientific. Dr Fernandez de la Concha is a consultant for Abbott, Medtronic, and Biotronik. Dr Cantillon is a consultant for Abbott and Boston Scientific. Dr Neužil has reported that he has no relationships relevant to the contents of this paper to disclose.

PY - 2023/7

Y1 - 2023/7

UR - http://www.scopus.com/inward/record.url?scp=85157969215&partnerID=8YFLogxK

U2 - 10.1016/j.jacep.2023.01.031

DO - 10.1016/j.jacep.2023.01.031

M3 - Letter

C2 - 36951813

AN - SCOPUS:85157969215

SN - 2405-500X

VL - 9

SP - 1187

EP - 1189

JO - JACC: Clinical Electrophysiology

JF - JACC: Clinical Electrophysiology

IS - 7

ER -